The Effectiveness of Intraperitoneal Carboplatin-Taxane Combination Chemotherapy in Stage 3 Ovarian Cancer

Our purpose is comparing the effectiveness of IP and IV chemotherapy in patients with epithelial ovarian cancer (EOC). This is a pilot study for improving protocol of chemotherapy for EOC. Methods: A retrospective, single-center study included 103 patients with EOC between March 2005 and December 2022. Forty-eight patients received IV chemotherapy; 45 received IP chemotherapy. In the IP group, carboplatin (AUC5) was administered on day 1 and paclitaxel (135 mg/m2) was on day 2 through IP port, every three weeks for 6 cycles. In the IV group carboplatin and paclitaxel were administered intravenously with the same dosage and the same schedule. The primary endpoint was progression free survival. Results: The median PFS was longer in the IP group than in the IV group (65 months vs. 59 months) with 31% lower risk of recurrence (HR=0.69, 95% CI: 0.35-1.34, P=0.27). The median PFS of stage 3 was 47 months (95% CI: 15.8-78.1) with the IP chemotherapy and 19 months (95% CI: 16.22-21.77) with IV chemotherapy (HR=0.36, 95% CI: 0.14-0.95, P=0.04). Median OS for patients of stage 3 was 110 months and 67 months in the IP group and IV group (P=0.03), respectively (HR=0.17, 95%CI: 0.03-1.08, P=0.06). Conclusion: IP chemotherapy has a survival benefit in patients with stage 3 EOC. There were no significant differences in adverse events between two groups.